Research progress of efavirenz individualized medication guided by patient's genotype and therapeutic drug monitoring

The plasma concentration of anti-HIV drug efavirenz is closely related to drug adverse reactions and efficacy. However, in some HIV-1 infected patients who were taken standard dose of efavirenz, their plasma concentration is varied greatly due to the difference of genetic and physio-pathological factor. It causes virological failure and increased incidence of adverse reactions. Many researchers point out that individualized medication is a good solution. This review describes the research progress on efavirenz individualized medication guided by genotype and therapeutic drug monitoring(TDM) for the reference to optimize the use of efavirenz in HIV-1 infected patients.